Tuesday, November 27, 2007

The perils of gene therapy

Targeted Genetics resumed a gene therapy trial yesterday after a halt by the FDA due to the death of one of the participants. The therapy was aimed at alleviating arthritis by injecting patients with a virus genetically modified to encode an anti-inflammatory protein. A federal gene therapy committee will discuss the implications of this death at an NIH conference in Washington on Dec. 3.


MC Masters

No comments: